66684-64-8 Usage
Uses
Used in Pharmaceutical Industry:
3,4-Difluoro-6-Nitroanisole is used as a chemical intermediate for the synthesis of pharmaceuticals, contributing to the development of new medications. Its unique structure allows it to be a key component in the formulation of drugs that address specific health conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 3,4-Difluoro-6-Nitroanisole is utilized as an intermediate in the production of agrochemicals, which are essential for enhancing crop protection and improving agricultural yields.
Used in Specialty Chemicals Production:
3,4-Difluoro-6-Nitroanisole also serves as a building block in the manufacturing process of specialty chemicals, which are high-value compounds used in various applications, including but not limited to coatings, adhesives, and advanced materials.
Safety Considerations:
Check Digit Verification of cas no
The CAS Registry Mumber 66684-64-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,6,6,8 and 4 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 66684-64:
(7*6)+(6*6)+(5*6)+(4*8)+(3*4)+(2*6)+(1*4)=168
168 % 10 = 8
So 66684-64-8 is a valid CAS Registry Number.
InChI:InChI=1/C7H5F2NO3/c1-13-7-3-5(9)4(8)2-6(7)10(11)12/h2-3H,1H3
66684-64-8Relevant academic research and scientific papers
ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR
-
Page/Page column 894, (2021/06/26)
The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES
-
Paragraph 0440-0442, (2020/02/08)
The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
CHEMICAL COMPOUNDS
-
, (2012/02/06)
The present invention relates to compounds of Formula (I) and/or Formula (Ia): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the tr
